Recent Advances in Angiogenesis and Antiangiogenesis

Inhibitors of Angiogenesis Based on Thrombospondin-1

Author(s): Giulia Taraboletti and Katiuscia Bonezzi

Pp: 112-126 (15)

DOI: 10.2174/978160805004810901010112

* (Excluding Mailing and Handling)


Angiogenesis-driven pathologies, including cancer, are sustained by a preponderance of angiogenic factors over endogenous inhibitors of new-vessel formation. Restoring this balance represents a logical therapeutic strategy to treat these pathologies. Therefore, endogenous inhibitors of angiogenesis, and in particular thrombospondin-1 (TSP-1), are a powerful source of potential antiangiogenic tools. Different therapeutic approaches have been proposed to exploit the antiangiogenic properties of TSP-1, including TSP-1 fragments, synthetic peptides and peptidomimetics, gene therapy strategies and agents that up-regulate TSP-1 expression. This review focuses on the possibility of exploiting TSP-1 for the design of antiangiogenic agents, with particular reference on their use in antineoplastic therapies.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy